NICE Backs Imbruvica In CLL On Price Cut Despite Outcome Uncertainties
Executive Summary
It looks likely AbbVie. and Johnson & Johnson's Imbruvica (ibrutinib) will be made routinely available on the NHS in England and Wales for treating chronic lymphocytic leukemia after an undisclosed price cut was offered and data further considered by the UK HTA NICE.